1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Inflammatory Skin Diseases – Pipeline Review, H1 2013

Inflammatory Skin Diseases – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 43 pages

Inflammatory Skin Diseases – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Inflammatory Skin Diseases - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Skin Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Skin Diseases. Inflammatory Skin Diseases - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Inflammatory Skin Diseases.
- A review of the Inflammatory Skin Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Inflammatory Skin Diseases pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Inflammatory Skin Diseases.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Inflammatory Skin Diseases pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Inflammatory Skin Diseases - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Inflammatory Skin Diseases Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Inflammatory Skin Diseases 7
Inflammatory Skin Diseases Therapeutics under Development by Companies 9
Inflammatory Skin Diseases Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Inflammatory Skin Diseases Therapeutics - Products under Development by Companies 14
Inflammatory Skin Diseases Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Inflammatory Skin Diseases Therapeutics Development 16
Johnson and Johnson 16
Biofrontera AG 17
Warner Chilcott Limited 18
CREABILIS Therapeutics S.r.l. 19
APEIRON Biologics AG 20
Inflammatory Skin Diseases - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
BF-PC-21 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
BF-PC-18 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
BF-PC-13 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
CT-327 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
WC-3027 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
stratagraft skin tissue - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
APN-201 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
JNJ-28610244 - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
Inflammatory Skin Diseases Therapeutics - Drug Profile Updates 36
Inflammatory Skin Diseases Therapeutics - Dormant Products 38
Inflammatory Skin Diseases - Product Development Milestones 39
Featured News and Press Releases 39
Jul 14, 2010: Perrigo Company Confirms Patent Challenge For Clobetasol Propionate Emulsion Foam 39
Mar 20, 2008: Perrigo company announces launch of clobetasol propionate foam 39
Mar 11, 2008: Perrigo company receives final approval on Clobetasol Propionate foam 39
Sep 01, 2006: Perrigo receives tentative approval for Clobetasol Propionate foam 40
Mar 02, 2006: Medicis Announces FDA Approval of Broader Indication for VANOS 40
Sep 22, 2005: Aqua Pharmaceuticals Licenses Cordran and Monodox for the United States 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 43
Disclaimer 43



List of Tables

Number of Products Under Development for Inflammatory Skin Diseases, H1 2013 7
Products under Development for Inflammatory Skin Diseases - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Johnson and Johnson, H1 2013 16
Biofrontera AG, H1 2013 17
Warner Chilcott Limited, H1 2013 18
CREABILIS Therapeutics S.r.l., H1 2013 19
APEIRON Biologics AG, H1 2013 20
Assessment by Monotherapy Products, H1 2013 21
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Stage and Molecule Type, H1 2013 25
Inflammatory Skin Diseases Therapeutics - Drug Profile Updates 36
Inflammatory Skin Diseases Therapeutics - Dormant Products 38



List of Figures

Number of Products under Development for Inflammatory Skin Diseases, H1 2013 7
Products under Development for Inflammatory Skin Diseases - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 21
Assessment by Route of Administration, H1 2013 22
Assessment by Stage and Route of Administration, H1 2013 23
Assessment by Molecule Type, H1 2013 24
Assessment by Stage and Molecule Type, H1 2013 25

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Radiodermatitis Market: - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Radiodermatitis Market: - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

Radiodermatitis, also known as radiation dermatitis, is a significant symptom caused by radiation therapy used in treating cancer as well as exposure to radiation during nuclear disasters. During cance ...

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Eczema - Market Insights, Epidemiology and Market Forecast-2023

Eczema - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Eczema - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.